Brainomix raises €18.4M Series B round

16 December 2021· Oxford, United Kingdom· health, medical_imaging, ai, b2b, b2g, pure_software

To fund expansion into new markets and new therapeutic indications, including lung fibrosis and cancer, and enable pharmaceutical partnerships

Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care. With this investment extension, we are well-positioned to enhance customer support across the US and Europe, accelerating the seamless integration of our technology into existing clinical workflows and expanding access to life-saving treatments.

Dr Michalis Papadakis, co-founder and chief executive

Investors

LeadBoehringer Ingelheim Venture Fund
Also participating
Parkwalk AdvisorsTencent HoldingsOxford University Innovation Fund

About Brainomix

Headquarters
Oxford, United Kingdom
Founded
2010
Team Size
51–200
Sectors
healthmedical_imagingaib2bb2gpure_software

Source: https://www.brainomix.com/brainomix-announces-16m-21-2m-series-b-investment/